Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
Cardiology Clinics
|
November 26, 2008
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors
John F Paolini, Harold E Bays, Christie M Ballantyne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 19, 2023
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Yanfen Guan, Amy Puenpatom, Matthew G Johnson, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
September 18, 2021
Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
August 7, 2021
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
The Oncologist
|
May 30, 2024
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer
Wasat Mansoor, Seongjung Joo, Josephine M Norquist, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 19, 2022
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study
Michele Maio, Mayur M Amonkar, Josephine M Norquist, et al.
Liver Cancer
|
August 8, 2024
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394
Shukui Qin, Weijia Fang, Zhenggang Ren, et al.
Cancer
|
November 24, 2020
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240
Baek-Yeol Ryoo, Philippe Merle, Amit S Kulkarni, et al.
Journal of Hepatology
|
March 28, 2025
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study
Changhoon Yoo, Makoto Ueno, Heinz-Josef Klümpen, et al.
The Lancet. Oncology
|
April 4, 2021
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
Thierry Andre, Mayur Amonkar, Josephine M Norquist, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
Cardiology Clinics
|
November 26, 2008
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors
John F Paolini, Harold E Bays, Christie M Ballantyne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 19, 2023
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Yanfen Guan, Amy Puenpatom, Matthew G Johnson, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
September 18, 2021
Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
August 7, 2021
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
The Oncologist
|
May 30, 2024
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer
Wasat Mansoor, Seongjung Joo, Josephine M Norquist, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 19, 2022
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study
Michele Maio, Mayur M Amonkar, Josephine M Norquist, et al.
Liver Cancer
|
August 8, 2024
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394
Shukui Qin, Weijia Fang, Zhenggang Ren, et al.
Cancer
|
November 24, 2020
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240
Baek-Yeol Ryoo, Philippe Merle, Amit S Kulkarni, et al.
Journal of Hepatology
|
March 28, 2025
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study
Changhoon Yoo, Makoto Ueno, Heinz-Josef Klümpen, et al.
The Lancet. Oncology
|
April 4, 2021
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
Thierry Andre, Mayur Amonkar, Josephine M Norquist, et al.
Page
of 4